글로벌 인크레틴 모방제 시장 규모, 점유율 및 추세 분석 보고서 – 산업 개요 및 2031년까지의 예측

인크레틴 모방제 시장 분석

인크레틴 모방제 시장은 전 세계적으로 당뇨병 발병률이 증가함에 따라 급속한 성장을 경험했으며, 효과적인 치료법에 대한 수요가 급증했습니다. 혈당 수치를 관리하고 장기 합병증을 줄이는 데 중점을 두면서 의료 서비스 제공자는 입증된 효능을 위해 인크레틴 모방제에 관심을 기울이고 있습니다. 인크레틴 호르몬의 작용을 모방하도록 설계된 이 약물은 특히 기존 치료법으로 어려움을 겪는 환자에게 당뇨병 치료에 대한 새로운 접근 방식을 제공합니다. 그 결과, 인크레틴 모방제는 현대 당뇨병 관리의 초석이 되었으며, 제약 혁신과 시장 도달 범위 모두에서 확장을 주도했습니다.

인크레틴 모방제 시장 규모

글로벌 인크레틴 모방제 시장 규모는 2023년에 127억 9천만 달러로 평가되었으며, 2031년까지 288억 2천만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 10.69%입니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

보고 범위 및 시장 세분화       

Incretin Mimetics Market Definition

Incretin mimetics are a class of medications used in the treatment of type 2 diabetes. They mimic the action of incretin hormones, which stimulate insulin release from the pancreas and decrease glucagon secretion, ultimately lowering blood sugar levels. These drugs can help regulate blood glucose levels and may also promote weight loss.

Incretin Mimetics Market Dynamics

Drivers

• Growing Technological Advancements Enhance the Formulation Incretin Mimetics

Innovations such as sustained-release formulations and novel delivery methods improve patient convenience and compliance. Advancements in drug design and molecular engineering allow for the creation of more potent and long-acting Incretin Mimetics, offering superior glycemic control. These technological breakthroughs broaden the therapeutic options and contribute to the continued growth and competitiveness of the Incretin Mimetics market, meeting the evolving needs of patients and healthcare providers alike.

For instance, In April, 2024, Novo Nordisk launches a groundbreaking once-weekly formulation of its Incretin Mimetic, Victoza (liraglutide), heralding a new era in diabetes management. This technological leap simplifies treatment regimens, enhances patient adherence, and promises improved long-term outcomes, marking a significant advancement in the fight against diabetes.

• Demand for Incretin Mimetics Increases due to Clinical Efficacy

Extensive clinical studies consistently showcase the remarkable effectiveness of these medications in managing blood sugar levels, reducing HbA1c levels, and promoting weight loss in patients with type 2 diabetes. Furthermore, Incretin Mimetics demonstrate a lower risk of hypoglycemia compared to some traditional diabetes treatments, enhancing their appeal among healthcare providers and patients alike. This robust clinical efficacy not only instills confidence in prescribing physicians but also drives patient demand, thereby fostering sustained growth within the Incretin Mimetics market.

Opportunities

• Growing Regulatory Support leads to the Adoption of Incretin Mimetics by Healthcare Systems

Approval and endorsement by regulatory agencies such as the FDA (in the U.S.) and the EMA (in Europe) provide crucial validation for healthcare providers, fostering confidence in prescribing Incretin Mimetics. Regulatory oversight also ensures that manufacturers adhere to rigorous standards throughout the drug development process, from preclinical research to clinical trials and post-market surveillance. This regulatory backing enhances market acceptance and facilitates widespread adoption of Incretin Mimetics by healthcare systems and practitioners worldwide.

• Patient-Centric Benefits Enhances Patient Experience in Diabetes Management

Features such as once-weekly dosing and low risk of hypoglycemia enhance treatment adherence and patient satisfaction, leading to improved long-term outcomes. Moreover, the convenience offered by Incretin Mimetics aligns with modern lifestyles, reducing the burden of daily medication regimens for individuals managing diabetes. These patient-friendly attributes not only promote better treatment compliance but also contribute to positive word-of-mouth referrals and patient loyalty. As a result, the market for Incretin Mimetics continues to expand, driven by a focus on enhancing the overall patient experience in diabetes management.

Restraints/Challenges

• High Cost limits the Adoption of Incretin Mimetics Medications

Incretin Mimetics medications can be expensive, placing financial strain on patients, particularly those without adequate insurance coverage. The affordability barrier limits access to treatment, especially in regions with limited healthcare resources or for economically disadvantaged individuals. High costs may deter physicians from prescribing Incretin Mimetics as first-line therapies, opting for more affordable alternatives.

• Complexity of Treatment Regimens Reduces the Growth Potential of Incretin Mimetics

Incretin Mimetics are often prescribed as part of combination therapy with other diabetes medications, leading to intricate treatment regimens that can be challenging for patients to follow accurately. Managing multiple medications, each with its dosing schedule and administration instructions, increases the risk of non-adherence and medication errors. Moreover, complexity can contribute to treatment fatigue and dissatisfaction among patients, potentially leading them to seek simpler alternatives.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Incretin Mimetics Market Scope

The market is segmented on the basis of indication, drugs, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Indication

• Diabetes
• Others

Drugs

• Exenatide
• Liraglutide
• Sitagliptin
• Saxagliptin
• Alogliptin
• Linagliptin
• Others

Application

• Solid Tumors
• Blood-related Tumor

Route of Administration

• Oral
• Parenteral
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Incretin Mimetics Market Regional Analysis

The market is analysed and market size insights and trends are provided by indication, drugs, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the market due to its key manufacturers, leveraging established infrastructure and expertise. Substantial investments in research and development foster innovation, driving the region's competitive edge and robust healthcare expenditure bolsters both product demand and quality standards. A skilled workforce contributes to efficient production and technological advancement, further solidifying North America's stronghold in the market.

아시아 태평양 지역은 정부 인식 강화 프로그램으로 인해 글로벌 인크레틴 모방제 시장에서 강력한 성장을 경험했으며, 의료 전문가와 환자 사이에서 이러한 약물에 대한 지식이 증가하여 활용도가 높아졌습니다. 제네릭 약물의 가용성으로 인해 인크레틴 모방제가 더 쉽게 접근 가능하고 저렴해졌으며, 시장 확장이 더욱 촉진되었습니다. 이러한 결합된 요인은 아시아 태평양 지역에서 상당한 성장을 촉진했으며, 예측 기간 내내 글로벌 시장의 상승 궤도에 핵심적으로 기여했습니다.

보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 다운스트림 및 업스트림 가치 사슬 분석, 기술 트렌드 및 포터의 5가지 힘 분석, 사례 연구와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 몇 가지 포인터입니다. 또한 글로벌 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 국내 관세 및 무역 경로의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.

인크레틴 모방제 시장 점유율

시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우세입니다. 제공된 위의 데이터 포인트는 글로벌 인크레틴 모방제 시장과 관련된 회사의 초점에만 관련이 있습니다.

시장에서 활동하는 주요 기업은 다음과 같습니다.

• 파이저 주식회사(미국)
• 아스트라제네카(영국)
• 브리스톨-마이어스 스퀴브 회사(미국)
• Teva Pharmaceutical Industries Ltd(이스라엘)
• Sun Pharmaceutical Industries Ltd(인도)
• 마일런 NV(미국)
• 노바티스 AG(스위스)
• 루팡(인도)
• Cipla Inc(인도)
• Aurobindo Pharma(인도)
• Fresenius SE & Co. KGaA(독일)
• 사노피(프랑스)
• F. 호프만-라 로슈 유한회사(스위스)
• 애벗(미국)

SKU-54080